Last reviewed · How we verify
Oral Prednisone
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in cells.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in cells. Used for Adrenocortical insufficiency, Rheumatoid arthritis, Systemic lupus erythematosus.
At a glance
| Generic name | Oral Prednisone |
|---|---|
| Also known as | Prednisone, steroids, corticosteroids, prednisone, Placebo |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology, Oncology (supportive) |
| Phase | FDA-approved |
Mechanism of action
Prednisone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory mediators. The result is broad anti-inflammatory and immunosuppressive effects across multiple organ systems.
Approved indications
- Adrenocortical insufficiency
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Polymyalgia rheumatica
- Giant cell arteritis
- Asthma and COPD exacerbations
- Allergic reactions
- Inflammatory bowel disease
- Autoimmune hemolytic anemia
- Thrombocytopenia
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (anxiety, irritability)
- Increased appetite and weight gain
- Osteoporosis (with chronic use)
- Immunosuppression and increased infection risk
- Gastrointestinal upset
- Acne and skin changes
- Adrenal suppression (with prolonged use)
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (PHASE1, PHASE2)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Prednisone CI brief — competitive landscape report
- Oral Prednisone updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI